Frequently Asked Questions
The market is segmented based on Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Disease Type (Benign Focal Amyotrophy of ALS, Infantile Spinal Muscular Atrophy, Juvenile Spinal Muscular Atrophy, Kugelberg-Welander Disease, Primary Lateral Sclerosis, Progressive Bulbar Palsy, Spinal Muscular Atrophy, Upper Motor Neuron Disease, Werdnig-Hoffman Disease and Wohlfart-Disease), Drug Type (Riluzole, Edaravone (Radicava) and Others), Distribution Channel (Hospital Pharmacies, and Retail and Online Pharmacies), Treatment type (Chemotherapy and Stem Cell Therapy), End User (Hospitals, Homecare, Specialty Clinics and Others) – Industry Trends and Forecast to 2030.
.
The Global Als Treatment Market size was valued at USD 664.12 USD Million in 2022.
The Global Als Treatment Market is projected to grow at a CAGR of 4.6% during the forecast period of 2023 to 2030.
The major players operating in the market include Sanofi, Mitsubishi Tanabe Pharma Corporation, BrainStorm Cell Limited, Mylan N.V., Ionis Pharmaceuticals, Biogen, Covis Pharma, Apotex , Ascend Laboratories LLC, ITF Pharma, Genervon Biopharmaceuticals LLC, Bausch Health Companies , ORPHAZYME A/S, Orion Pharma , KRINGLE PHARMA , Amylyx Pharmaceuticals , Sun Pharmaceutical Industries , Advanz Pharmaceutical, Otsuka Pharmaceutical Co. .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
